Pramlintide

Brand names: Symlin®

Mechanism of action: Amylin receptor agonist; Slows gastric emptying; Suppresses postprandial glucagon secretion; Increases satiety; Reduces post-meal glucose excursions

Approved indications: Adjunct treatment in adults with type 1 diabetes using mealtime insulin; Adjunct treatment in adults with type 2 diabetes using mealtime insulin

Proposed indications: Obesity; Weight maintenance; Binge eating disorder; Combination therapy with GLP-1 agonists

Administration: Subcutaneous injection before major meals — Before meals

Compare with: CagrilintideSemaglutideTirzepatide

Evidence rating: Grade A — Well-established efficacy in insulin-treated diabetes. Growing interest in obesity treatment, particularly in combination with GLP-1 receptor agonists.

Landmark trials: Randomized controlled trials — Demonstrated improved postprandial glucose control and modest weight loss in both type 1 and type 2 diabetes.

Common side effects: Nausea, Vomiting, Decreased appetite, Headache

Serious risks: Severe hypoglycemia (particularly in type 1 diabetes if insulin is not adjusted); Gastrointestinal intolerance

Drug interactions: Delays gastric emptying and may alter absorption of oral medications; Increased hypoglycemia risk when combined with insulin

Monitoring: HbA1c, Blood glucose (including postprandial levels), Weight, Frequency of hypoglycemia, Gastrointestinal tolerance

Legal status: Prescription required. This is an FDA-approved medication available only through a licensed prescriber — dosing is determined by your prescriber based on your medical history and is not provided here.

Regulatory status: FDA Approved • EMA: Not widely marketed

Contraindications: Confirmed gastroparesis; Hypoglycemia unawareness; Hypersensitivity to pramlintide or formulation components

Pregnancy & breastfeeding: Use only if the potential benefit outweighs the risk. Data during breastfeeding are limited.

Ratner RE, et al. (2004). Amylin replacement with pramlintide as an adjunct to insulin therapy. Diabetes Care, 27(3), 724–730. Whitehouse F et al. (2002). A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care.